YM150

Phase 2Small molecule

Astellas

YM150 is one of 85 small molecule programs targeting Venous Thromboembolism. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Venous ThromboembolismActive, not recruiting

Acute Coronary SyndromeActive, not recruiting

Atrial FibrillationActive, not recruiting

Venous ThromboembolismPhase 2/Phase 3

Active, not recruiting

Acute Coronary SyndromePhase 2

Active, not recruiting

Atrial FibrillationPhase 2

Active, not recruiting

Competition

Competitive Landscape

376 competitors in Atrial Fibrillation

#DrugCompanyPhaseTrials

YM150

Astellas

Phase 2

2 2

Calquence

AstraZeneca

Preclinical

1 3

Calan

VVal Adams

Preclinical

4 4

Ondexxya

UUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology

Preclinical

1 5

Romazicon

CConrado Roberto Hoffmann Filho

Preclinical

1 6

Brukinsa

BBeOne Medicines

Preclinical

1 7

Imbruvica

PPharmacyclics LLC.

Preclinical

1 8

Anticoagulants

Sanofi

Preclinical

2 9

Low-Molecular-Weight Heparin

Daiichi Sankyo

Preclinical

1 10

Statin

Bristol-Myers Squibb

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Venous Thromboembolism7 trials

Prevention of Venous Thromboembolism in Patients Undergoing Elective Total Knee Replacement Surgery

Completed· Astellas logo

Astellas·Phase 2/3·NCT00917254·369 enrolled

Prevention of Venous Thromboembolism in Patients Undergoing Elective Total Hip Replacement Surgery

Completed· Astellas logo

Astellas·Phase 2/3·NCT00913120·610 enrolled

A Study to Assess the Effect of YM150 for Prevention of Venous Thromboembolism in Patients Undergoing Major Abdominal Surgery

Completed· Astellas logo

Astellas·Phase 3·NCT00942435·156 enrolled

Show 4 more trials

YM150 for Prevention of Venous Thromboembolism in Patients With Acute Medical Illness

Completed· Astellas logo

Astellas·Phase 3·NCT01028950·52 enrolled

Prevention of Recurrence of Venous Thromboembolism in Patients With a History of Venous Thromboembolism

Completed· Astellas logo

Astellas·Phase 3·NCT00937820·87 enrolled

Prevention of Venous Thromboembolism in Subjects Undergoing Hip Fracture Surgery or Surgery in the Lower Extremities

Completed· Astellas logo

Astellas·Phase 3·NCT00937911·101 enrolled

Factor Xa Inhibitor for Prevention of Venous Thromboembolism in Patients Undergoing Elective Total Knee Replacement

Completed· Astellas logo

Astellas·Phase 2·NCT00408239·367 enrolled

Tics3 trials

A Study to Compare the Pharmacokinetics of YM150 Formulation-A and Formulation-B

Completed· Astellas logo

Astellas·Phase 1·NCT01125657·44 enrolled

A Pharmacokinetic Study to Investigate the Effect of Food on the Pharmacokinetics of YM150 Tablet

Completed· Astellas logo

Astellas·Phase 1·NCT01125670·24 enrolled

A Pharmacokinetic Study to Investigate the Effect of Food on the Pharmacokinetics of YM150

Completed· Astellas logo

Astellas·Phase 1·NCT01118559·24 enrolled

Atrial Fibrillation2 trials

A Study Evaluating Safety and Tolerability of YM150 Compared to Warfarin in Subjects With Atrial Fibrillation

Completed· Astellas logo

Astellas·Phase 2·NCT00938730·1,280 enrolled

Direct Factor Xa Inhibitor YM150 for Prevention of Stroke in Subjects With Non-Valvular Atrial Fibrillation

Completed· Astellas logo

Astellas·Phase 2·NCT00448214·448 enrolled

Concentration2 trials

A Study to Investigate the Effect of YM150 on the Plasma Concentration of Digoxin in Healthy Subjects

Completed· Astellas logo

Astellas·Phase 1·NCT01514812·24 enrolled

A Study to Investigate the Plasma Concentration of YM150 After Repeated Administration to Elderly Subjects

Completed· Astellas logo

Astellas·Phase 1·NCT01514825·36 enrolled

Factor Xa Inhibitor1 trial

Factor Xa Inhibitor YM150 for the Prevention of Blood Clot Formation in Veins After Scheduled Hip Replacement (ONYX-2)

Completed· Astellas logo

Astellas·Phase 2·NCT00353678·1,141 enrolled

5 more indications

Hip Replacement Surgery1 trial

A Study Evaluating Efficacy and Safety of YM150 Compared to Enoxaparin in Subjects Undergoing Hip Replacement Surgery

Completed· Astellas logo

Astellas·Phase 2/3·NCT00902928·1,992 enrolled

TED1 trial

A Study to Find Out How YM150 is Absorbed Into and Eliminated From the Body in Healthy Male Subjects

Completed· Astellas logo

Astellas·Phase 1·NCT01657981·6 enrolled

Female1 trial

A Study to Evaluate the Safety and Tolerability of YM150 in Healthy Caucasian and Japanese Male and Female Subjects, and to Assess the Effect That Gender May Have on Its Actions in the Body

Completed· Astellas logo

Astellas·Phase 1·NCT01655056·82 enrolled

Acute Coronary Syndrome1 trial

Study Evaluating Safety, Tolerability and Efficacy of YM150 in Subjects With Acute Coronary Syndromes

Completed· Astellas logo

Astellas·Phase 2·NCT00994292·1,276 enrolled

Knee Replacement Surgery1 trial

A Study to Evaluate the Safety and Efficacy of YM150 in Patients With Knee Replacement Surgery

Completed· Astellas logo

Astellas·Phase 2·NCT00595426·685 enrolled

Sources

References

[1]
ClinicalTrials.gov — 20 trial records for YM150. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — YM150 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for YM150. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Astellas company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: Astellas

YM150

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Venous Thromboembolism7 trials

Tics3 trials

Atrial Fibrillation2 trials

Concentration2 trials

Factor Xa Inhibitor1 trial

Hip Replacement Surgery1 trial

TED1 trial

Female1 trial

Acute Coronary Syndrome1 trial

Knee Replacement Surgery1 trial

References

Drug Info

Quick Facts

Related News